The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria

BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by chronic complement-mediated hemolysis. Eculizumab, a humanized monoclonal antibody against the terminal complement protein C5, potently reduces chronic intravascular hemolysis. We tested the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin Seok, Lee, Jong Wook, Kim, Byoung Kook, Lee, Je-Hwan, Chung, Jooseop
Formato: Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023054/
https://www.ncbi.nlm.nih.gov/pubmed/21253430
http://dx.doi.org/10.5045/kjh.2010.45.4.269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023054/
https://www.ncbi.nlm.nih.gov/pubmed/21253430
http://dx.doi.org/10.5045/kjh.2010.45.4.269

Ejemplares similares